Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07341204
Eligibility Criteria:
Inclusion Criteria:
* Clinical diagnosis of ASD, ADHD, SLD, or DCD confirmed by a licensed clinician or documented in medical/educational records (DSM-5 or equivalent).
* Parent/guardian consent and participant assent (age-appropriate).
* Ability to follow simple verbal instructions and to participate in 25-minute VR sessions twice weekly for 6 weeks.
* Stable medication regimen for attention- or behavior-related medications for ≥4 weeks prior to baseline (or not taking such medications).
* Visual and auditory ability adequate for VR tasks (with or without usual corrective lenses/hearing aids).
* Availability to attend all scheduled sessions at the clinical site across the 6-week period.
Exclusion Criteria:
* History of photosensitive epilepsy or any uncontrolled seizure disorder.
* Severe intellectual disability or severe communication impairment that prevents understanding/participation (e.g., non-responsive to simple commands required by the VR tasks).
* Severe visual, auditory, or motor impairment that prevents safe or functional use of the VR system (e.g., inability to hold controllers or view the headset even with correction).
* Recent (within 6 months) significant brain injury or neurosurgery. Significant history of motion sickness, severe vestibular disorder, or prior intolerance to immersive VR.
* Any medical or implanted device contraindicated for VR/headset use (if applicable).
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
9 Years
Maximum Age:
18 Years
Study:
NCT07341204
Study Brief:
Protocol Section:
NCT07341204